Tag Archives: IPCC

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech Patenting Event: BIO’s 2012 Fall IPCC in Charleston, South Carolina


BIO’s 2012 Fall IPCC Conference event on November 12-14 gathers biotech in-house counsels to provide and discuss relevant IP developments.  The Honorable Jimmie V. Reyna, Circuit Judge for the United States Court of Appeals for the Federal Circuit keynotes this year’s program along with the Honorable Judge Sally Gardner Lane, Administrative Patent Judge, Trial Division, Board of Patent Appeals and Interferences. Find program topics and speakers below.  Click here for the full agenda.   Picking the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

2012 Fall Event Preview


The 2012 BIO International Convention, the global event for biotechnology, held at the Boston Convention & Exhibition Center in Boston, Mass., wrapped this June. The event hosted a record 25,291 partnering meetings and highlighted a broad array of top-level speakers addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 49 states and 65 countries. See what BIO President and CEO Jim Greenwood Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

American Invents Act Strategies Highlighted at the IPCC Conference


By David Saravitz, Alston + Bird Day 2 of the 2012 BIO Intellectual Property Counsels’ Committee (IPCC) Spring Conference kicked off with a panel on the America Invents Act (AIA).  The panel focused on how practitioners and the U.S. Patent & Trademark Office (USPTO) are dealing with various provisions of this new patent act. Mr. Ira Finkelstein, Senior Patent Counsel with Baxter Healthcare, led off the session initially discussing the first-inventor-to-file provision of the AIA (§ Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Biotech Patent Case Law Updates at the IPCC


By John W. Cox, Counsel at Alston+Bird LLP The Spring 2012 BIO Intellectual Property Counsels’ Committee (IPCC) Conference, held in Austin, Texas, provided an excellent forum for intellectual property (IP) practitioners in the biotech industry to socialize, network, and participate in panel discussions focusing on the dynamic developments in the patent laws.  The conference began for the general participants over margaritas and Tex-Mex fare, where attendees were already discussing recent Supreme Court and Federal Circuit decisions Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,